Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. Cellyan Biotechnology Co's Total Liabilities for the quarter that ended in Mar. 2026 was $3.26 Mil. Cellyan Biotechnology Co's Total Assets for the quarter that ended in Mar. 2026 was $12.84 Mil.
Therefore, Cellyan Biotechnology Co's Liabilities-to-Assets Ratio for the quarter that ended in Mar. 2026 was 0.25.
Cellyan Biotechnology Co (NAS:HKPD) Liabilities-to-Assets Explanation
Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.
Cellyan Biotechnology Co Liabilities-to-Assets Related Terms
Cellyan Biotechnology Co Liabilities-to-Assets Historical Data
* Premium members only.
The historical data trend for Cellyan Biotechnology Co's Liabilities-to-Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cellyan Biotechnology Co Liabilities-to-Assets Chart
HKPD vs COSM, YI, MEDS: Liabilities-to-Assets Comparison
For the Medical Distribution subindustry, Cellyan Biotechnology Co's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cellyan Biotechnology Co Liabilities-to-Assets vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Cellyan Biotechnology Co's Liabilities-to-Assets distribution charts can be found below:
* The bar in red indicates where Cellyan Biotechnology Co's Liabilities-to-Assets falls into.
Cellyan Biotechnology Co Liabilities-to-Assets Calculation
Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.
Cellyan Biotechnology Co's Liabilities-to-Assets Ratio for the fiscal year that ended in Mar. 2026 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cellyan Biotechnology Co (HKPD) has a Liabilities-to-Assets of 0.25 as of Mar. 2026. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on Cellyan Biotechnology Co and its competitors.
Is Cellyan Biotechnology Co's Liabilities-to-Assets too high?
Cellyan Biotechnology Co's current Liabilities-to-Assets is 0.25. Overall, Cellyan Biotechnology Co has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Cellyan Biotechnology Co's Liabilities-to-Assets compare to COSM and YI?
Cellyan Biotechnology Co's Liabilities-to-Assets of 0.25 can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Liabilities-to-Assets for a Medical Distribution company?
A good Liabilities-to-Assets depends on the Medical Distribution industry context. However, Liabilities-to-Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Liabilities-to-Assets mean?
A high Liabilities-to-Assets can signal that a stock is expensive relative to its fundamentals. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on Cellyan Biotechnology Co and its competitors. Cellyan Biotechnology Co's current Liabilities-to-Assets is 0.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cellyan Biotechnology Co stock overvalued right now?
Cellyan Biotechnology Co (HKPD) has a current Liabilities-to-Assets of 0.25. The current Liabilities-to-Assets is 0.25. Cellyan Biotechnology Co's overall GF Score™ is 18/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Liabilities-to-Assets calculated?
Liabilities-to-Assets is calculated from a company's financial statements. For Cellyan Biotechnology Co (HKPD), the current Liabilities-to-Assets is 0.25 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cellyan Biotechnology Co Ltd formerly, Hong Kong Pharma Digital Technology Holdings Ltd operates in two main categories: OTC pharmaceutical cross-border e-commerce supply chain services, conducted through its Hong Kong subsidiary, Joint Cross Border, which it refers to as the Supply Chain Services division, and OTC pharmaceutical cross-border procurement and distribution, conducted through its Hong Kong subsidiary, V-Alliance, which it referred to as the Procurement and Distribution division. Based in Hong Kong, Joint Cross Border has established itself as a provider of third-party supply chain services in Mainland China's OTC pharmaceutical cross-border e-commerce market.
18GF Score
Get the complete analysis for HKPD
Liabilities-to-Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKPD has been successfully added to your 
